The FDA approved lasmiditan (Reyvow, Eli Lilly) for the treatment of acute migraine with or without aura in adults. Lasmidtan is not indicated for prevention of migraine.
Lasmiditan has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists). Its therapeutic effects are presumably mediated by agonist effects at this receptor; however, the precise mechanism is unknown, according to Eli